IMS Health Files for IPO
IMS Health has filed a registration statement with the US Securities and Exchange Commission
IMS Health, which provides information, services and technology for the healthcare industry, that allows them to measure and improve performance, has filed a registration statement with the U.S. Securities and Exchange Commission for proposed initial public offering of its common stock.
In the clinical trials area, IMS Health acquired both DecisionView and TTC in 2012. DecisionView provided software solutions for patient enrollment in clinical trials, and TTC benchmarking and analytics solutions for negotiating costs of clinical trials through its GrantPlan database.
The full relase can be read here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
